Active	Status	Sponsor type	Region	Phase	Filter
3 Active 14 Inactive 17 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
BI 1358894 / Boehringer Ingelheim
NCT05103657 / 2021-003154-23: A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder	Completed	2	318	Europe, US, RoW	BI 1358894, Placebo	Boehringer Ingelheim, Boehringer Ingelheim AB, Boehringer Ingelheim Finland Ky, , Boehringer Ingelheim RCV GmbH & Co KG	Post-Traumatic Stress Disorder	10/23	11/23
NCT04521478 / 2019-004264-21: A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression	Completed	2	389	Europe, Canada, Japan, US, RoW	BI 1358894, Placebo, Quetiapine	Boehringer Ingelheim	Depressive Disorder, Major	01/24	02/24
NCT05934942: A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood	Terminated	1	29	Europe	Yasmin®, BI 1358894	Boehringer Ingelheim	Healthy	02/24	02/24